WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Review on Sulfonylureas

Shahuraje S. Kashid, Dhanashri Puri, Vijaysinh Sable, Rahul Jadhav .

Locmagal College of Pharmacy

ABSTRACT :-

The fundamental and clinical pharmacology of sulfonylureas is covered in this review. It evaluates sulfonylureas' benefits and drawbacks objectively and contrasts how different sulfonylureas are used in diverse therapeutic settings. The authors provide helpful advice to enable the safe and efficient administration of this class of medications, helping to maximize the use of this affordable therapeutic alternative in resource-constrained settings like developed countries.

Keyword :- Diabetes, Oral antidiabetic drug, Safety

Introduction :-

The first oral glucose-lowering drugs to be used in clinical settings were sulfonylureas (SU), which have long been used to treat diabetes. About 20% of recently started oral diabetes treatments are made up of these.OneWhether used alone or in conjunction with other medications, they form the cornerstone of oral diabetes treatment in many regions of the world, including South Asia.1, 2, Over the past 50 years, they have assisted in providing countless millions of people with symptomatic alleviation, improved quality of life, and euglycemia. They cannot be "whisked away" because to their affordable price, availability as fixed dose combinations with metformin, and comfortable acceptance by both doctors and patients with diabetes2.The World Health Organisation and all nations have listed one or both of the SUs as necessary oral anti-diabetic medications. As a result, encouraging the sensible use of these medications is essential to ensuring their safety, tolerability, and effectiveness in controlling blood sugar.

Mechanism of Action –

Sulfonylureas are a class of oral antidiabetic drugs that work primarily by stimulating insulin secretion from pancreatic beta cells. Here’s a breakdown of their mechanism of action:

Binding to Sulfonylurea Receptor (SUR) on Beta Cells: Sulfonylureas bind to specific sulfonylurea receptors (SUR) on the surface of pancreatic beta cells. These receptors are part of ATP-sensitive potassium channels (KATP channels).

Inhibition of KATP Channels: Upon binding, sulfonylureas inhibit ATP-sensitive potassium channels (KATP channels). Normally, these channels are open in the resting state of the beta cell, allowing potassium ions to exit the cell, thereby keeping the cell membrane polarized and preventing calcium influx.

Depolarization of Beta Cells: Inhibition of KATP channels leads to depolarization of the beta cell membrane. This depolarization occurs because potassium ions are no longer leaving the cell, causing the cell membrane potential to become more positive.

Calcium Influx: Depolarization triggers voltage-gated calcium channels to open, allowing calcium ions to enter the beta cell.

Insulin Secretion: The increase in intracellular calcium concentrations stimulates exocytosis of insulin-containing granules from the beta cells into the bloodstream.

Overall Effect: By enhancing insulin secretion, sulfonylureas help to lower blood glucose levels in individuals with type 2 diabetes mellitus. They are particularly effective when there is still significant functional pancreatic beta cell mas

Efficacy of Sulfonylureas :-

Sulfonylureas are a class of oral medications used primarily for the treatment of type 2 diabetes. They work by stimulating insulin release from the pancreas, thereby lowering blood glucose levels. The efficacy of sulfonylureas in managing diabetes is well-established, particularly in lowering HbA1c levels, which reflects average blood glucose levels over a period of time.

Key points regarding the efficacy of sulfonylureas include:

Blood Glucose Control: Sulfonylureas effectively lower blood glucose levels by stimulating insulin secretion. This helps in reducing HbA1c levels, which is a critical marker of long-term glucose control.

Long-Term Use: They have been used for decades and have demonstrated durability in maintaining glycemic control over time, especially when used in combination with other diabetes medications.

Side Effects: While effective, sulfonylureas can cause side effects such as hypoglycemia (low blood sugar) and weight gain, which may limit their use in some patients.

Adherence: They are generally taken once or twice daily, which can aid in patient adherence to treatment regimens.

Individual Variability: Efficacy can vary among individuals, and factors such as age, duration of diabetes, and other health conditions can influence their effectiveness.

Combination Therapy: They are often used in combination with other classes of diabetes medications (e.g., metformin) to achieve optimal glycemic control.

Cost: Sulfonylureas are generally affordable compared to newer diabetes medications, making them accessible in many healthcare settings.

In summary, sulfonylureas remain a cornerstone in the management of type 2 diabetes due to their effectiveness in lowering blood glucose levels. However, healthcare providers consider individual patient factors and potential side effects when determining the most appropriate treatment regimen.

Safety of Sulfonylureas :-

Sulfonylureas are a class of medications commonly used to treat type 2 diabetes by stimulating insulin secretion from the pancreas. They have been in clinical use for many years and are generally considered safe and effective when used appropriately. However, like all medications, they come with potential risks and side effects:

Hypoglycemia: This is the most common side effect of sulfonylureas. They lower blood sugar by stimulating insulin release, which can sometimes lead to dangerously low blood sugar levels if not managed properly.

Weight gain: Some individuals may experience weight gain while taking sulfonylureas, although this can vary among different medications in the class.

Allergic reactions: While rare, some people may be allergic to sulfonylureas, which can manifest as skin rash, itching, or more severe reactions.

Gastrointestinal disturbances: These medications may occasionally cause nausea, vomiting, or diarrhea.

Liver toxicity: Although uncommon, some sulfonylureas can affect liver function, particularly in people with pre-existing liver disease.

Cardiovascular effects: There have been debates and studies regarding the cardiovascular safety of sulfonylureas, particularly in comparison to newer diabetes medications. Current evidence suggests that individual risks may vary, and it's essential to consider the overall cardiovascular risk profile of each patient.

It's crucial for individuals taking sulfonylureas to be monitored regularly by their healthcare provider to assess blood sugar levels, adjust medication dosages as needed, and watch for any signs of side effects. Overall, these medications have a long history of use and are still valuable options for managing diabetes, particularly in those who cannot tolerate or afford newer alternatives.

Recent Development :-

Recent developments in sulfonylureas primarily revolve around their efficacy, safety profile, and potential new applications. Here are some key points:

1. *Efficacy and Safety*: Sulfonylureas continue to be effective in lowering blood glucose levels by stimulating insulin release from pancreatic beta cells. They are particularly useful in patients with type 2 diabetes who have preserved pancreatic function. However, concerns about hypoglycemia (low blood sugar) remain, especially in elderly patients or those with renal impairment.

2. *Cardiovascular Effects*: Studies have investigated the cardiovascular safety of sulfonylureas. While older generation sulfonylureas like glyburide have been associated with increased cardiovascular risk, newer agents like gliclazide have shown a more favorable cardiovascular safety profile.

3. *Newer Formulations*: Pharmaceutical companies are developing newer formulations to enhance the pharmacokinetic profiles of sulfonylureas, aiming for reduced risk of hypoglycemia and once-daily dosing regimens.

4. *Combination Therapies*: Sulfonylureas are frequently used in combination with other antidiabetic agents, such as metformin, to achieve better glycemic control. Combination therapies are being studied to optimize efficacy while minimizing side effects.

5. *Potential Applications*: Research is exploring potential benefits of sulfonylureas beyond diabetes treatment. For instance, some studies suggest they may have neuroprotective effects and could be beneficial in conditions like Alzheimer's disease.

Overall, while sulfonylure as remain an important treatment option for type 2 diabetes, ongoing research aims to refine their use, improve safety, and explore new therapeutic applications.

Conclusion :-

In conclusion, sulfonylureas have been a cornerstone in the treatment of type 2 diabetes for many years, primarily due to their ability to effectively lower blood glucose levels by stimulating insulin secretion. They work by binding to ATP-sensitive potassium channels on pancreatic beta cells, leading to insulin release. Despite their efficacy, sulfonylureas are associated with several drawbacks including an increased risk of hypoglycemia, weight gain, and potential long-term effects on pancreatic beta cell function. Nevertheless, sulfonylureas remain valuable treatment options, especially in resource-limited settings where cost considerations are significant. Their affordability and familiarity make them accessible to a wide range of patients. The choice of antidiabetic therapy should be individualized, taking into account factors such as patient preferences, comorbidities, and the overall risk-benefit profile of each medication

Reference :-

1. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN,Schneeweiss S, et al. Patterns of medication initiation in newlydiagnosed diabetes mellitus: quality and cost implications. Am JMed 2012;125:302.e1-7

.2. Eldor R, Raz I. Diabetes therapy--focus on Asia: second-linetherapy debate: insulin/secretagogues. Diabetes Metab Res Rev2012;28 Suppl 2:85-9

.3. Seino S. Cell signalling in insulin secretion: the molecular targetsof ATP, cAMP and sulfonylurea. Diabetologia 2012;55:2096-108.

4. Hirst JA, Farmer AJ, Dyar A, Lung TW, Stevens RJ. Estimating theeffect of sulfonylurea on HbA1c in diabetes: a systematic reviewand meta-analysis. Diabetologia 2013;56:973-84

.5. Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, etal. Association of sulphonylurea treatment with all-cause andcardiovascular mortality: a systematic review and meta-analysis ofobservational studies. Diab Vasc Dis Res 2013;10:302-14

6. Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A,et al. Sulphonylurea monotherapy for patients with type 2diabetes mellitus. Cochrane Database Syst Rev 2013;4:CD009008.

7. Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, etal. Cancer risk associated with use of metformin and sulfonylureain type 2 diabetes: a meta-analysis. Oncologist 2012;17:813-22

.8. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS.Metformin and sulfonylureas in relation to cancer risk in type IIdiabetes patients: a meta-analysis using primar y data ofpublished studies. Metabolism 2013;62:922-34.

9. Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenomics of oralantidiabetic medications: current data and pharmacoepigenomicperspective. Pharmacogenomics 2011;12:1161-91.

10. Scheen AJ. Pharmacokinetic considerations for the treatment ofdiabetes in patients with chronic kidney disease. Expert OpinDrug Metab Toxicol 2013;9:529-50.

11. Ahmadieh H, Azar ST. Liver disease and diabetes: association,pathophysiology, and management. Diabetes Res Clin Pract2014;104:53-62.